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A B S T R A C T
 
Background: The emergence of resistance has been demonstrated in cancer treatment 
centers where prophylaxis with fluoroquinolone is used. 
Objective: Considering the importance of epidemiological monitoring as a strategy in 
choosing protocols involving antibiotics, this study aimed to evaluate the emergence of 
quinolone resistance and changes in the local epidemiology in a hematopoietic stem cell 
transplant service.
Methods: For this study, 60 positive cultures before the prophylactic use of levofloxacin 
(period A: 2007-2008) and 118 cultures after starting the use of prophylactic levofloxacin 
(period B: 2010-2011) were evaluated.
Results: Resistance increased for all the different types of bacteria isolated (from 46.0% to 
76.5%; p-value = 0.0002). Among Gram-negative bacteria, resistance increased from 21.4% 
to 60.7% (p-value = 0.0163) and among Gram-positive bacteria, it increased from 55.6% 
to 82.9% (p-value = 0.0025). The use of levofloxacin increased from 19.44 defined daily 
doses per 1,000 patient-days in period A to 166.64 in period B. The use of broad spectrum 
antibiotics remained unchanged. Considering bacteria associated with infection, 72 and 76 
were isolated in periods A and B, respectively. There was a reduction in the rate of Gram-
negative bacteria in cultures associated with infection (3.81 vs. 2.00 cultures/1,000 patient-
days; p-value = 0.008).
Conclusion: The study of prophylaxis with levofloxacin demonstrated that there was a 
decrease in infections by Gram-negative bacteria; however, bacterial resistance increased, 
even though the use of broad-spectrum antibiotics remained unchanged. Constant 
monitoring of local epidemiology combined with research on clinical outcomes is needed 
to evaluate the effectiveness of prophylaxis.
 © 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 
All rights reserved. 
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Introduction
Patients undergoing hematopoietic stem cell transplantation 
(HSCT) during the neutropenic period have a high risk of fever, 
with a reported occurrence greater than 80%.1
In an attempt to decrease the risk of associated complications, 
it has been routine for several decades to use antimicrobials 
as clinical prophylaxis during the neutropenic phase of HSCT 
patients. Fluoroquinolones were introduced in the 1980s as 
a prophylactic agent, and since then, this has been the most 
commonly used antibiotic class prescribed in this setting.2
Some aspects of the benefits brought by prophylactic 
fluoroquinolone use are still questioned. Reductions in the time 
of febrile neutropenia and infections in neutropenic patients 
are well-documented;1-3 however, the impact of prophylaxis 
on mortality is still discussed. Although some meta-analyses 
have shown a reduction of this indicator,4,5 individually, most 
studies did not detect significant decreases.1,3 Due to the few 
benefits in reducing mortality and also due to the threat of 
developing bacterial resistance, studies and guidelines advise 
the use of prophylaxis only in high-risk patients, defined by 
the severity and/or duration of neutropenia.1,6 Other studies 
even discourage its use, particularly in centers where there is 
high incidence of resistant bacteria.7-9
Considering that changes in local bacterial epidemiology 
can impact treatment effectiveness and patient safety, this 
study assessed whether there was emergence of quinolone 
resistance related to the increased use of levofloxacin in one 
HSCT service. Possible changes in the epidemiology of bacteria 
associated with healthcare-associated infection (HCAI) after 
the introduction of clinical prophylaxis with levofloxacin were 
also investigated.
Methods
The HSCT Service of the Hospital das Clínicas of the 
Universidade Federal do Paraná (HC/UFPR) adopted prophylaxis 
with levofloxacin for neutropenic patients in the middle of 
2009. An oral dose of 500 mg is used once daily from the initial 
conditioning or the infusion of hematopoietic stem cells until 
granulocyte recovery or the development of fever and early 
empirical antimicrobial therapy.10
Patients admitted from January of 2007 to December of 2011 
were studied. The period from January of 2007 to December 
of 2008 was the period preceding the use of prophylactic 
levofloxacin (period A), and the period from January of 2010 
to December of 2011 was characterized by the prophylactic 
use of levofloxacin (period B). The period from January to 
December of 2009 was not evaluated to avoid the possibility 
of bias in the results, since the transition of the protocol 
occurred in the month of July. Regarding readmissions, if a 
patient was hospitalized during both of the studied periods, 
the characteristics of this patient and culture results were 
considered separately for each period.
The susceptibility of the etiologic agents isolated in 
cultures and the epidemiology of bacteria linked to HCAI 
were evaluated in both periods. The frequency of resistance 
to quinolones was evaluated by microbiological investigations; 
with the preparation of bacterial susceptibility profiles for 
periods A and B. Cultures of clinical samples with positive 
results obtained from hospitalized patients were analyzed. 
The results considered for the sensitivity profile were: 
resistant, intermediate, and sensitive. For patients with two 
diagnostic cultures, different strains for the same etiologic 
agent were considered when the interval between collections 
was longer than one month or when there was a change in 
sensitivity/resistance to at least one antimicrobial agent tested 
independent of the interval between collections. The use of 
levofloxacin, cefepime, and meropenem was assessed by 
defined daily dose (DDD) per 1,000 patient-days.
The Kirby-Bauer method, performed by the diagnostic 
support unit of the bacteriology department of in HC/UFPR, was 
used to evaluate the susceptibility profile, in accordance with 
the recommendations of the National Committee for Clinical 
and Laboratory Standardization. 
Monthly routine epidemiological surveillance records, 
provided by the hospital’s infection control department, were 
used for HCAI data. The hospital infection rate, the relationship 
between confirmed clinical and laboratory HCAI, the frequency 
of etiological agents, and the topography of infections were 
analyzed.
The concepts and classification of HCAI followed the criteria 
of the Centers for Disease Control and Prevention (CDC) and 
the Brazilian criteria for healthcare-associated infections 
from 2009. Sepsis by coagulase-negative staphylococci (CNS) 
was defined when the microorganism was identified in two 
consecutive blood cultures or when the patient was treated 
empirically with vancomycin due to the results of a culture.
 Statistical analyses were used to evaluate the association 
between the frequency of resistance in the two periods studied, 
the frequency of etiologic agents, and the characteristics of the 
population. The statistical software R was used for analysis, 
applying Pearson’s chi-squared test, Fisher’s exact test, and the 
Poisson test. p-values < 0.05 were considered to be statistically 
significant. The analysis was performed by the UFPR statistics 
laboratory.
Results
Patients’ characteristics
A total of 378 patients were analyzed during the study period; 
145 were hospitalized in period A and 233 were hospitalized 
in period B. Table 1 describes the characteristics of patients 
admitted during both periods.
The average ages were 16.24 years and 22.13 (p-value = 
0.007), the percentages of men were 62.1% and 54.9% (p-value = 
0.170), and the numbers of HSCTs performed were 161 and 244, 
for periods A and B, respectively. The most prevalent diagnoses 
in both periods were leukemia, severe aplastic anemia, and 
Fanconi anemia. The two groups were evenly distributed 
with respect to gender, but the distributions regarding age 
and type of diagnosis (p-value = 0.030) were statistically 
different. Analyzing separately the frequency of leukemia, the 
commonest diagnosis in both groups, no significant difference 
was observed (p-value = 0.170).
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Bacterial susceptibility and antibiotics use
In relation to the susceptibility profile, a total of 178 cultures 
were analyzed; 60 were isolated in period A and 118 were 
isolated in period B. The distribution of bacteria isolated 
in the HSCT service is shown in Table 2. The sensitivity to 
quinolones was tested in 50 and 98 cultures in periods A 
and B, respectively. In the analysis of the sensitivity profile, 
microorganisms with intermediate sensitivity were considered 
resistant; in the clinical practice, the same conduct is 
generally used for both intermediate and resistant results. 
One bacterium with intermediate sensitivity was isolated in 
period A and three in period B. Table 3 shows the frequency 
of bacterial resistance into the two periods. The correlation 
between bacterial resistance to quinolones and the use of 
levofloxacin is shown in Figure 1. There was a significant 
increase in resistance in period B compared to period A for all 
the different types of bacteria isolated (from 46.0% to 76.5%; 
p-value = 0.0002), for Gram-negative bacteria (GN; from 21.4% 
to 60.7%; p-value = 0.0163) and Gram-positive bacteria (GP; from 
55.6% to 82.9%; p-value = 0.0025). For Enterobacteriaceae, E. 
coli, P. aeruginosa, and CNS, the increased resistance was not 
statistically significant.
Considering the use of antibiotics in the period, there was 
an increase in the use of levofloxacin from 19.44 DDD per 1,000 
patient-days in period A to 166.64 in period B. Regarding the 
systemic use of antibiotics used to treat in presence of clinical 
evidence of infection, there was an increase in meropenem from 
4.59 to 5.33 DDD per 1,000 patient-days and a slight decrease in 
cefepime from 3.75 to 3.32 DDD per 1,000 patient-days.
 
 
Characteristic
Period A
(n = 145)
Period B
(n = 233)
 
 
p-valuen % n %
Average age - mean 16.2 
(13.5)
22.1 
(17.8)
0.007
Gender 0.170
    Male 90 62.1 128 54.9
    Female 55 37.9 105 45.1
Diagnosis 0.030
    Leukemia 48 33.1 81 34.8 0.170
        Acute 37 25.5 70 30.0
        Chronic 11 7.6 11 4.8
    Severe aplastic anemia 30 20.7 42 18.0
    Fanconi anemia 28 19.3 39 16.7
    Wiskott-Aldrich 
      syndrome
8 5.5 5 2.1
    Adrenoleukodystrophy 8 5.5 4 1.7
    Myelodysplastic  
      syndrome
5 3.4 10 4.3
    Lymphoma 2 1.4 16 6.9
    Multiple myeloma 1 0.7 8 3.4
    Others 15 10.3 28 12.0
Table 1 - Characteristics of patients hospitalized during 
periods A and B.
 
Microorganism
Period A Period B
n %a n %a
Gram-negative 14 23.3 29 24.6
    Escherichia coli 1 1.7 7 5.9
    Pseudomonas aeruginosa 3 5.0 6 5.1
    Acinetobacter baumanii 5 8.3 9 7.6
    Sphingomonas paucimobilis 1 1.7 1 0.8
    Moraxella sp. 2 3.3 0 0
    Acinetobacter sp. 1 1.7 0 0
    Morganella morganii 1 1.7 0 0
    Enterobacter cloacae 0 0 4 3.4
    Stenotrophomonas maltophilia 0 0 2 1.7
Gram-positive 46 76.7 89 75.4
    Coagulase-negative staphylococci 24 40.0 59 50.0
    Enterococcus faecium 7 11.7 15 12.7
    Staphylococcus aureus 4 6.7 5 4.2
    Enterococcus faecalis 4 6.7 4 3.4
    Viridans group streptococcus 6 10.0 4 3.4
    Enterococcus avium 1 1.7 0 0
    Enterococcus gallinarum 0 0 1 0.8
    Enterococcus sp. 0 0 1 0.8
Totalb 60 100.0 118 100.0
aPercentage considering the total number of bacteria isolated.  
bTotal bacteria (Gram-positive + Gram-negative). 
Table 2 - Distribution of microorganisms used to 
elaborate the bacterial susceptibility profile isolated 
from different samples in the Hematopoietic Stem Cell 
Transplant Service in Periods A and B.
Period A Period B
Resistant + 
intermediate 
bacteria
Total 
tested
Resistant + 
intermediate 
bacteria
Total 
tested
 
p-valuen % n %
GN+GP 23 46.0 50 75 76.5 98 0.0002
GN 3 21.4 14 17 60.7 28 0.0163
Enterobacteria 1 50.0 2 10 90.9 11 0.2949
E. coli 0 0 1 6 85.7 7 0.2500
P. aeruginosa 0 0 3 3 50.0 6 0.4643
GP 20 55.6 36 58 82.9 70 0.0025
CNS 17 70.8 24 52 88.1 59 0.1018
GN: Gram-negative; GP: Gram-positive; CNS: coagulase-negative 
staphylococci.
Table 3 - Susceptibility of isolated bacteria in the 
Hematopoietic Stem Cell Transplant Service in periods 
A and B.
Epidemiology of health care-associated infection
A total of 297 infections were recorded in period A and 456 
infections in period B; the rates of HCAI were 55.7% and 63.9%, 
respectively. The most frequent infections in both periods were 
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sepsis and pneumonia (Table 4). Of the total infections, 124 
were confirmed by laboratory tests in period A; 69 (55.6%) were 
caused by bacteria, 45 (36.3%) were caused by viruses, and ten 
(8.1%) were caused by fungi. In period B, 147 infections were 
confirmed; 76 (51.7%) were caused by bacteria, 47 (32.0%) were 
caused by viruses, and 24 (16.3%) were caused by fungi.
there was an increase in the rate of infection by Pseudomonas 
aeruginosa in period B. The rate of infection by GP bacteria 
was similar in both study periods (4.77 vs. 4.60 cultures/1,000 
patient-days; p-value = 0.431). The rate of Clostridium difficile 
decreased in period B (1.79 vs. 0.87 cultures/1,000 patient-days; 
p-value = 0.035) and the rate of Streptococcus viridans increased 
(0.0 vs. 0.35 cultures/1,000 patients-day; p-value = 0.043).
 
Location
Period A Period B
n % n %
Sepsis 190 64.0 306 67.1
Pneumonia 24 8.1 48 10.5
Gastrointestinal 21 7.1 19 4.2
Respiratory tract except pneumonia 20 6.7 16 3.5
Urinary tract 16 5.4 21 4.6
Eyes, ears, and nose 9 3.0 17 3.7
Cardiovascular 8 2.7 7 1.5
Skin and soft tissues 5 1.7 17 3.7
Central nervous system 4 1.3 3 0.7
Reproductive tract 0 0 2 0.4
Total 297 100.0 456 100.0
Table 4 - Distribution of healthcare-associated 
infections by location in periods A and B.
The distribution of isolated bacteria associated with 
infections is shown in Table 5. A decrease in the rate of GN 
bacterial infections was observed in period B when compared 
to period A (3.81 vs. 2.00 cultures/1,000 patient-days; p-value 
= 0.008). The rate of infection by Enterobacteriaceae did not 
change significantly between periods A and B (1.91 vs. 1.04 
cultures/1,000 patient-days; p-value = 0.053). Decreases in the 
rates of Acinetobacter sp. and Klebsiella pneumoniae contributed 
significantly to reducing the rate of GN infection. In contrast, 
 
Microorganism
Period A Period B  
p-valueInfection 
ratea
n Infection 
ratea
n
Gram-negative 3.81 32 2.00 23 0.008
    Enterobacteria 1.91 16 1.04 12 0.053
    Escherichia coli 0.72 6 0.69 8 0.477
    Acinetobacter sp. 0.72 6 0.17 2 0.028
    Enterobacter cloacae 0.36 3 0.26 3 0.344
    Acinetobacter baumanii 0.24 2 0.09 1 0.197
    Stenotrophomonas 
maltophilia
0.12 1 0.17 2 0.388
    Klebsiella pneumoniae 0.48 4 0 0 0.009
    Achromobacter 
xylosoxidans
0.24 2 0 0 0.047
    Moraxella sp. 0.24 2 0 0 0.047
    Gram-negative non-      
      fermenter bacilli
0.12 1 0 0 0.119
    Citrobacter freundii 0.12 1 0 0 0.119
    Enterobacter gergoviae 0.12 1 0 0 0.119
    Klebsiella oxytoca 0.12 1 0 0 0.119
    Pantoea agglomerans 0.12 1 0 0 0.119
    Pseudomonas stutzeri 0.12 1 0 0 0.119
    Pseudomonas aeruginosa 0 0 0.43 5 0.029
    Pseudomonas fluorescens 0 0 0.09 1 0.188
    Serratia marcenscens 0 0 0.09 1 0.188
Gram-positive 4.77 40 4.60 53 0.431
    CNS 2.03 17 2.26 26 0.365
    Clostridium difficile 1.79 15 0.87 10 0.035
   Staphylococcus aureus 0.48 4 0.35 4 0.326
    Enterococcus faecalis 0.24 2 0.09 1 0.197
    Enterococcus faecium 0.12 1 0.35 4 0.156
    Bacillus sp. 0.12 1 0.0 0 0.119
    Corynebacterium ap. 0 0 0.09 1 0.188
    Enterococcus gallinarum 0 0 0.09 1 0.188
    Viridans group 
      streptococcus 
0 0 0.35 4 0.043
    Exiguobacterium 
acetylicum
0 0 0.09 1 0.188
    Rhodococcus 0 0 0.09 1 0.188
    Total 72 76
CNS: coagulase-negative staphylococci.  
a Infection rate calculated by the number of positive cultures/1,000 
patient-days.
Table 5 - Distribution of microorganisms linked to health 
care-associated infections during periods A and B.
Figure 1 – Correlation between the frequency of quinolone 
resistance in periods A and B indicated by bars, and the annual 
consumption of levofloxacin indicated by black diamonds, where 
A = 2007, B = 2008, C = 2009, D = 2010, and E = 2011.
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Discussion
Bacterial susceptibility and antibiotic use
Fluoroquinolones began to be used as prophylaxis for 
neutropenic patients in 1980. Two decades after this class of 
antimicrobials was introduced in cancer treatment centers, 
several studies demonstrated changes in the epidemiology of 
etiologic agents.9,11,12 Moreover, changes in the susceptibility 
profiles of these agents to quinolones have been associated 
with resistance to other classes of drugs.
The sensitivity profile was prepared to assess bacterial 
susceptibility (Table 3) in the HSCT service. Data evaluated 
included results from different biological samples. The 
bacteria isolated from this set of cultures were not necessarily 
associated with infections (Table 2). The epidemiology of 
etiologic agents will be discussed only for bacteria linked to 
HCAI due to their greater clinical relevance.
An increase in resistance to quinolones from 46.0% to 76.5% 
(p-value = 0.0002) was observed when considering all the 
bacteria tested from the HSCT service. A retrospective study 
evaluating 258 patients using prophylaxis with levofloxacin 
combined with penicillin and doxycycline in a HSCT center 
demonstrated that there was an increase of 60% in resistance 
to fluoroquinolone.13
Another study in Italy with 269 patients from 2001 to 
2009 associated the use of levofloxacin with the emergence 
of resistance among GP bacteria; only 13% were sensitive to 
quinolones.14 In the present study, the frequency of sensitive 
GP bacteria in the period when the use of levofloxacin 
increased was 17.1%.
Historically, the group of Enterobacteria, with the 
pathophysiological mechanism of the translocation of bacteria 
from gastrointestinal treatment, is one of the greatest causes 
of bacteremia in neutropenic patients.2,9 In the present study, 
resistance did not increase significantly for this group. A 
larger discrepancy was observed in the susceptibility study 
by Saito et al., who demonstrated a decrease in the resistance 
of Enterobacteria isolated in blood cultures (from 75% to 
17%; p-value = 0.0078) when the use of levofloxacin was 
restricted. The authors concluded that restrictions on the 
use of prophylaxis with levofloxacin reduce the frequency of 
resistance.1,2
Studies demonstrate that variations in resistance to 
quinolones are related to both the amount of quinolones used 
in the same institution and the frequency of use at different 
institutions. In a prospective study with 823 patients and 
148 isolated bacteria conducted over 16 months, E. coli was 
resistant to quinolones in 96.5% of patients who received 
prophylaxis and 44.4% in the group that did not.11 Another 
study conducted in two different cancer treatment centers 
in university hospitals, published in 2003 by Kern et al., 
reported a 64% to 79% proportion of E. coli fluoroquinolone-
resistant strains isolated from blood cultures in a hospital 
with widespread use of prophylactic ciprofloxacin, whereas 
in a hospital where the use of quinolones was lower, the rate 
ranged from 0 to 10%.15
In the current study, increased resistance to all the 
evaluated bacteria was found related to the increased use of 
levofloxacin in the service (Figure 1). This increase in resistance 
was statistically significant when analyzing all bacteria (GP 
and GN) and groups of GP and GN bacteria separately (Table 
3). When analyzed separately, the increase in the resistance 
for the group of Enterobacteria, Pseudomonas aeruginosa, E. coli, 
and CNS was not statistically significant, but the percentage 
increase in resistance can demonstrate a trend that should be 
acknowledged.
In addition, some studies have shown that resistance to 
quinolones is associated with cross-resistance to other classes 
of antibiotics.16,17 Among the mechanisms of resistance, 
mutations in the topoisomerase enzyme and DNA gyrase, 
transmission of multidrug-resistant genes by plasmids, and 
reduction of bacterial permeability have been described.17,18
Hopkins et al. reviewed the mechanisms of E. coli and 
Salmonella sp. resistance. Decreased fluoroquinolone uptake 
is caused by a decrease in bacterial permeability or over 
expression of efflux pumps. This resistance is the consequence 
of a multiple antimicrobial resistance (MAR) phenotype, and 
has been associated with cross-resistance to many structurally-
unrelated antimicrobials, such as beta-lactams, tetracyclines, 
nalidixic acid, and chloramphenicol. This MAR phenotype is 
also induced by other antimicrobials, such as tetracyclines, 
chloramphenicol, salicylates, and many other substances 
containing phenolic rings that reduce MAR repression.18
Resistance transmission can occur through the expression of 
a gene responsible for plasmid-mediated quinolone resistance 
(PMQR). It is known that this gene encodes a protein that 
protects DNA gyrase inhibition by fluoroquinolones. Hopkins 
et al. reported that the presence of the plasmid PMG252 caused 
a low basal level of resistance in E. coli. However, when added 
to the other mutations in the DNA gyrase enzyme, mutations 
resulting in decreased permeability and increased bacterial 
expression of efflux pumps promoted the selection of higher 
resistance. Furthermore, it was demonstrated that the plasmid 
PMG252 also confers resistance to aztreonam, ceftazidime, 
cefotaxime, cefoxitin, cefotetan, chloramphenicol, kanamycin, 
gentamicin, streptomycin, sulfafurazole, tobramycin, and 
trimethoprim.18
There are reports that the cross resistance to other 
structurally-unrelated antimicrobials may be related to the 
increase in multidrug resistant bacteria. In a retrospective 
study that analyzed 622 bacteremias in 2005 and 2006, 
prophylaxis with fluoroquinolone was compared with 
prophylaxis using other drugs and the absence of prophylaxis. 
Prophylaxis with quinolones was strongly associated with the 
isolation of methicillin-resistant S. aureus, as well as being 
associated with the emergence of multidrug-resistant E. coli 
and P. aeruginosa.19
Dancer described that quinolones were involved in a 
resistance mechanism and the increased virulence of S. aureus. 
The horizontal transfer of genetic elements of resistance and 
virulence, known as the SOS, could be induced by the use 
of quinolones. In addition, sub-inhibitory concentrations of 
quinolones would be involved in induction of adhesins that 
results in increased adherence of S. aureus to plasma proteins. 
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The increase in host cell intracellular persistence and a high 
cytotoxic capacity after removal of the antibiotic, related to the 
recurrence of infections, appears to be associated.20
Epidemiology of healthcare-associated infections
The reduction of infections with the use of prophylaxis with 
fluoroquinolone is documented in the literature.11,12 In a 
meta-analysis published in 1998, a significant reduction in the 
number of infections by GN microorganisms, microbiologically 
documented infections, and in total duration of fever was 
demonstrated compared to the group that did not use clinical 
quinolone prophylaxis.21
The present study found a significant increase in the rate of 
HCAI in period B. The larger number of complex transplants, 
including unrelated donors where the patient becomes 
more vulnerable to infections due to the more rigorous 
immunosuppressive treatment, may be a justification for this 
finding. Furthermore, differences in baseline characteristics 
of patients may be a factor that influences clinical severity.
Among the infections confirmed by laboratorial analysis, 
there was a proportional increase of fungi isolated in cultures. 
Although the number of laboratory confirmed infections is 
lower in relation to total HCAI (41.7% in period A and 32.2% 
in period B), this increase may also be related to the higher 
number of complex transplants performed. Furthermore, it is 
important to remember that, during period B, the HSCT unit 
was rebuilt, a condition that may predispose the environment 
to an increased dispersion of fungi, such as Aspergillus sp. and 
Fusarium sp.
Regarding bacteria linked to HCAI (Table 5), as demonstrated 
in other studies, there was a significant decrease in the 
frequency of GN bacteria. Saito et al. demonstrated a reduction 
in bacteremia caused by GN during the period when there was 
no restriction on the use of fluoroquinolones as prophylaxis 
(9.6 vs. 3.6%; p-value = 0.0008).12 Craig et al. also found a 
decrease in GN bacteremia in the period when prophylaxis 
with fluoroquinolones was used, compared to the period when 
no prophylaxis was used (4.7 vs. 1.8 cultures/1,000 patient-
days; p-value < 0.05).3
One expected result when using prophylaxis with 
fluoroquinolone is decreased GN bacterial infections, especially 
enterobacterial infections. In the present study, there was no 
significant decrease in the rate of enterobacterial infections. 
In contrast, a study conducted in Japan reported a significant 
decrease in the percentage of infection by Enterobacteriaceae 
on total patients (8.2 vs. 2.0; p-value < 0.0001) in the period 
without restrictions on prophylaxis with fluoroquinolones.12 
Furthermore, it is expected that with the use of quinolones 
there is a decrease in the consumption of broad-spectrum 
systemic antibiotics, as the use of this class for prophylaxis 
should decrease the number of episodes of bacterial infection. 
However, in the present study there was an increase in the 
consumption of meropenem in period B and a very slight 
decrease in the consumption of cefepime. Therefore, despite 
a decrease in the incidence of infections by GN bacteria, there 
was no decrease in the use of broad-spectrum antibiotics.
A significant increase in the rate of S. viridans infections was 
observed in the current study (p-value = 0.043). Other studies 
reported that this finding was related to the use of antibiotics 
at suboptimal minimum inhibitory concentrations followed 
by translocation of this agent from the gastrointestinal tract 
to the bloodstream.14 In another study, this event was related 
to severe mucositis associated with respiratory failure and 
shock.22
An increased frequency of Clostridium difficile diarrhea has 
been shown associated with the use of fluoroquinolones.23,24 
Quinolones in the gut only have a limited effect on the GN 
microbiota, causing the proliferation of the intact anaerobic 
population. Furthermore, the increase of diarrhea caused 
by C. difficile has been associated with ineffective infection 
prevention measures.17 A decrease in the proportion of 
infections caused by C. difficile (p-value = 0.035) was observed 
in this study, which can be explained by the implementation 
of precautionary contact measures and changes in the surface 
disinfection process in 2009 by the hospital’s infection control 
team.
Besides the risk of infection and colonization by multi-
resistant microorganisms, studies describe decreased 
effectiveness of prophylaxis with fluoroquinolones in centers 
where there is high prevalence of resistance to this class of 
antimicrobial agent.7,25 In a study conducted between 2000 
and 2003 to evaluate the usefulness of prophylaxis with 
fluoroquinolone in neutropenic patients, it was observed that 
in hospitals with a high frequency of resistance, prophylaxis 
did not prevent febrile events, nor decrease mortality rates.9 
Bow indicated that an analysis of the need to use prophylaxis 
with fluoroquinolone is important when the resistance is 
greater than 20%.17 Another study reported a decreased 
efficacy to reduce GN bacterial infections when the resistance 
was greater than 30%.26 
The aim of this study was to investigate the emergence 
of quinolone resistance among all bacteria detected and 
recorded in the period. The emergence of bacterial resistance 
observed only among bacteria associated with infection was 
not studied, making it difficult to extrapolate the data on 
resistance to HCAI. Another limitation is the small number 
of etiological agents isolated as compared to the total number 
of infections, decreasing the representation of the results. 
Furthermore, clinical outcomes, such as infection-related 
death, an important clinical impact indicator against changes 
in epidemiology and bacterial susceptibility, were not assessed 
in this study.
Conclusion
The use of prophylaxis with levofloxacin contributed to 
a decrease in the GN bacterial infection rate; however, 
there was no significant decrease in the rate of infection 
by Enterobacteriaceae and no decrease in the consumption 
of broad-spectrum antibiotics, which suggests that the 
effectiveness of the prophylaxis protocol should be reviewed. 
Considering the risks and benefits of antimicrobial prophylaxis, 
it is important to note the effect of prophylaxis on the 
emergence of bacterial resistance, reducing the effectiveness 
of empiric broad-spectrum antibiotics, and altering the effect 
of resistance on the clinical outcomes of neutropenic fever. 
Considering that increased resistance can lead to decreased 
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efficacy of prophylaxis with quinolones, and also that the 
prophylaxis decreases empirical treatment options, the use of 
this drug should be reconsidered. It is true that every decision 
regarding the choice of empiric or prophylactic drugs should be 
guided by the local epidemiology of each hospital. Therefore, it 
is necessary to monitor the profile of sensitivity and resistance 
of bacterial etiologic agents isolated in these centers, in order 
to guide the selection and/or change of therapeutic protocols.
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